In partnership with

  • Conferences
  • Disease Areas
  • News
  • Articles
  • Contact
    • Highlights from

    EULAR 2019

    European Congress of Rheumatology

    Madrid 12-15 June 2019

    The annual EULAR congress provides the exchange of scientific, clinical and patient-focussed information on a global basis. Read the full peer-reviewed Medicom Conference Report now.

    View the eBook of the full conference report.

    Articles

    Letter from the Editor

    article thumbnail

    Letter from the Editor

    Rheumatoid Arthritis

    Cohort study shows improvement during 25 years of RA treatment

    Filgotinib in RA patients with inadequate response or naïve to methotrexate

    Clinical effectiveness of fenebrutinib in RA patients with methotrexate or TNFi failure

    Peficitinib likely efficacious and safe

    Short methotrexate stop is safe in patients with RA

    Tofacitinib is safe according to real-world data analysis

    Switching upadacitinib and adalimumab is beneficial in refractory RA

    Tapering of prednisone in RA patients who achieved low disease activity or remission with tocilizumab

    Efficacy and safety of E6011 in RA patients with inadequate response to methotrexate

    Preliminary efficacy and safety data of RG6125 in RA patients with an inadequate response to TNF inhibitors

    Integrated 10-year analysis confirms safety profile abatacept

    Switching among multiple infliximab biosimilars does not cause immunogenicity

    Switch to sarilumab from adalimumab is efficacious and safe

    Axial Spondyloarthritis

    Treat-to-target approach emerging in axial spondyloarthritis

    NSAIDs consumption is linked to patient-assessed disease activity and decreases with use of TNF inhibitors

    Psoriatic Arthritis

    Efficacy and safety of ixekizumab versus adalimumab in patients with PsA

    Efficacy and safety of bimekizumab in patients with active PsA

    Filgotinib is efficacious and safe in PsA

    Ixekizumab improves signs and symptoms in TNFi-naïve PsA patients

    Etanercept and methotrexate as first-line treatment in PsA

    Unacceptable pain is common in patients with psoriatic arthritis

    Osteoarthritis and Osteoporosis

    What Is New in Osteoarthritis

    How to Treat Osteoporosis

    Miscellaneous

    Interstitial lung disease in rheumatic diseases and systemic sclerosis

    Emapalumab in patients with macrophage activation syndrome

    Support for tocilizumab use in giant cell arteritis

    The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.

    BACK TO TOP